Call for Abstract

2nd International Epigenetics and Epitranscriptomics Conference , will be organized around the theme “Novel Innovations and Techniques in Genetics for making Life Better”

Epitranscriptomics 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Epitranscriptomics 2019

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

Cancer is caused by the failure of checks and balances that control cell numbers in response to the needs of the whole organism. The inappropriate function of genes that promote or inhibit cell growth or survival can be caused by errors introduced into the genetic code itself or by faulty epigenetic mechanisms deciding which genes can and cannot be expressed. Two of the main methods are DNA methylation and histone modification. Methylation involves tacking a methyl group onto DNA. Epigenetic gene regulation collaborates with genetic alterations in cancer development. This is evident from every aspect of tumor biology including cell growth and differentiation, cell cycle control, DNA repair, angiogenesis, migration, and evasion of host immunosurveillance.


  • Track 1-1Cervical Cancer
  • Track 1-2Rhabdoid Tumor
  • Track 1-3Prostate Cancer
  • Track 1-4Brest Cancer
  • Track 1-5Chromatin dysregulation

The study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis, and treatment. Clinical epigenetics is being incorporated into patient management in oncology, as well as being explored for clinical applicability for other human pathologies such as neurological and infectious diseases and immune system disorders.


  • Track 2-1Cancer
  • Track 2-2Aging
  • Track 2-3Neurological Disease
  • Track 2-4Immune Disorders
  • Track 2-5Viral Infections
  • Track 2-6Rheumatic Heart Disease
  • Track 2-7Genetic Biomarkers

Epigenomes are made up of some chemical compounds and proteins which will attribute some genes and DNA that monitoring the production of proteins in a particular cell. The epigenomes have many alterations to the genome and some specialized cell that makes protein. The chemical modifications of epigenomes to the DNA and DNA-associated proteins in the cell, which alter gene expression, are heritable. The variations occur as a tissue development and differentiation that can be altered in response to environmental exposures and diseases. The epigenome has immediate applications for diagnostics. Changes to the epigenome can result in changes to the structure of chromatin and changes to the function of the genome.


  • Track 3-1Human Genome
  • Track 3-2Human Genomics Project
  • Track 3-3Plant Genomics
  • Track 3-4Histone Modification Assay
  • Track 3-5Epigenomics Compounds
  • Track 3-6Epigenetics Variation

The DNA methylation, post-translational histone modifications, and microRNA regulation are key mechanisms underlying healthy cardiovascular function as well as heart disease and its precursors. There is increasing evidence for the involvement of epigenetics in human diseases such as cancer, inflammatory disease, and CV disease. Other chronic diseases are also susceptible to epigenetic modification such as metabolic diseases including obesity, metabolic syndrome, and diabetes mellitus. There is much evidence for the modification of epigenetics by nutrition and exercise. Epigenetics is also involved in cardiovascular risk factors such as smoking, diabetes, and hypertension. Gene expression regulation through the interplay of DNA methylation and histone modifications is well-established, although the knowledge about the function of epigenetic signatures in cardiovascular disease is still largely unexplored


  • Track 4-1Cardiomyopathy
  • Track 4-2Hypertensive Heart Disease
  • Track 4-3Congenital Heart Disease
  • Track 4-4Pulmonary Heart Disease
  • Track 4-5Heart failure

Epigenetic biomarkers defined as the modifications of the genome with preserved DNA sequence. DNA methylation measurement in a cell, it may also be useful in improving early detection by measuring tumor DNA released into the blood. Molecular biomarkers are used routinely in a clinical setting to assess the medical state of patients and in several other medical contexts, including clinical trial endpoints, pharmaceutical development, and basic science research. The clinical validation of epigenetic biomarkers to allow the accurate prediction of the outcome of cancer patients and their potential chemosensitivity to current pharmacological treatments. A clinical example of a biomarker is plasma glucose.


  • Track 5-1Testis Cancers
  • Track 5-2Urological Cancers
  • Track 5-3Biomarkers for Lung Cancer
  • Track 5-4Breast Cancer
  • Track 5-5Ovarian Cancer
  • Track 5-6Malignant Rhabdoid Tumors
  • Track 5-7Induced Pluripotent Stem Cells (iPSCs)

The epigenetic basis of stem cell differentiation arises from the need to maintain gene expression patterns in both stem/progenitor cells and their differentiated progenies. As a stem cell differentiates, genes associated with self-renewal are down-regulated, while lineage-specific genes are activated. Chromatin modifying enzymes with opposing activities play a key role in the dynamic regulation of epigenetic marks. Defining the signaling pathways of these enzymes induced by differentiation-inducing cues is critical to understanding the mechanisms underlying stem cell differentiation. Furthermore, non-coding RNAs, especially microRNAs, provide additional layers for regulation of gene expression during cell fate specification. These multiple layers of regulation allow for the rapid transition of proliferating stem cells into their differentiated progenies.



  • Track 6-1Neural Stem Cells (NSCs)
  • Track 6-2Mesenchymal Stem Cells (MSCs)
  • Track 6-3Huntington’s Disease
  • Track 6-4Alzheimer’s Disease

Epigenetic component makes a difference to ensure the plant cells from the action of parasitic groupings such as transposable components, this defense can complicate the hereditary designing prepare through transcriptional quality silencing. The frequently occurring changes in plants which incorporates heritable or metastable changes causing varieties in epigenetic status. Hence, heritable epigenetic varieties, as well as hereditary variety, have the potential to drive common varieties of plants. Climate alter is without a doubt one of the most prominent dangers confronting both plants and creatures alike. With rising temperatures and irregular climate designs, dry spells have gotten to be a distant as well typical event worldwide.


  • Track 7-1Heritability of Epigenetic Marks
  • Track 7-2DNA Methylation in Plants
  • Track 7-3Crop Epigenetics: Hybridization and Heterosis
  • Track 7-4Natural Variation and Ecological Epigenetics
  • Track 7-5Stress-induced Epigenetics Changes
  • Track 7-6Epigenetics Regulation of Host-Pathogen Interactions

Epigenetic mechanisms can also be caused by environmental factors, such as diet, stress, exposure to toxic products, etc., and not merely the chance of genetic mutations. Epigenetic mechanisms governing animal phenotype and behavior. Epigenetic parameters orchestrating transgenerational effects, as well as hereditary disorders, and the often-overlooked areas of livestock immunity. Epigenetics has the potential to be very useful in animal breeding, as it may provide information relating to the heritability of complex traits and diseases.


  • Track 8-1Animal Models in Epigenetics Research
  • Track 8-2Animal Epigenetics Welfare
  • Track 8-3Animal Cloning Epigenetics
  • Track 8-4Genome Instability
  • Track 8-5Non-coding RNAs

Chromatin is a complex of DNA, RNA, and protein which packages very long DNA molecules into a more compact, denser shape, preventing the strands from becoming tangled, preventing DNA damage, and regulating gene expression and DNA replication. Chromosome mechanisms during replication and in response to DNA damage, ensuring the faithful inheritance of genetic and epigenetic information and maintaining genome stability. Epigenetic modification of the structural proteins in chromatin via methylation and acetylation also alters local chromatin structure and thus gene expression. The structure of chromatin networks is currently poorly understood and hence is an active area of research in molecular biology.


  • Track 9-1Sexual Chromosomes
  • Track 9-2Autosomal Chromosomes
  • Track 9-3Homo and Hetero Chromosome
  • Track 9-4Euchromatin
  • Track 9-5Nuclear Architecture
  • Track 9-6mRNA Methylation
  • Track 9-7miRNAs
  • Track 9-8RNA Editing

Epitranscriptomics can be defined as a functionally relevant change to the transcriptome that do not involve a change in the ribonucleotide sequence. The epitranscriptome, therefore, is defined as the study of posttranscriptional changes with vigor in both protein-coding and non-coding RNAs reveals a new complexity in gene regulation. Thus leading to 'Epitranscriptomics', organized with bioinformatics approaches and RNA modifications.T here are a few sorts of RNA alterations that affect quality expression. These adjustments happen to all sorts of cellular RNA counting, but not constrained to, ribosomal RNA (rRNA), Transfer ribonucleic acid RNA (tRNA), Messenger RNA (mRNA), and little atomic RNA (snRNA). The most collective and well-understood mRNA alteration at the show is the N6-Methyladenosine (m6A), which has been inspected to happen an normal of three times in each mRNA methylation.


  • Track 10-1Chromatin Modifications
  • Track 10-2Genomic Imprinting
  • Track 10-3mRNA Methylation
  • Track 10-4miRNAs
  • Track 10-5RNA Editing
  • Track 10-6RNA Modification Mapping
  • Track 10-7RNA Modification in Disease

Rare hereditary recessive diseases were thought to be expressed in offspring only when both parents carry a mutation in the causal gene. A rare disease is any condition that affects a small percentage of the population. Some rare diseases have an epigenetic component or involve epigenetically regulated genes. While genetic mutations are very rare, epigenetic changes are common and occur through our lifetimes. Some of the disorders due to mutations in histone modifiers are: Rubinstein-Taybi syndrome, Sotos syndrome (associated with mutations in the histone methyltransferase NSD1) or Weaver syndrome (due to mutations in the histone methyltransferase EZH2), among others. As new members of the epigenetic machinery are described, the number of human syndromes associated with epigenetic alterations increases.


  • Track 11-1Rett Syndrome (RTT)
  • Track 11-2Rubinstein-Tabi Syndrome (RTS)
  • Track 11-3Instability Facial Syndrome 1 (ICF1)
  • Track 11-4Sotos Syndrome

The emerging promise of translational epigenetics is highlighted in a range of stimulating clinical experiments underway on epigenetic pathways which offer new therapeutic approaches to cancer. Epigenetic modifications such as DNA methylation, histone modifications, and nucleosome remodeling have been found to be diagnostic hallmarks in a range of human tumors. The pathways which are regulated (or misregulated) via histone modifications, DNA methylation, and other epigenetic marks are being investigated as potential targets of such epi-drugs.

  • Track 12-1Controlling Gene expression
  • Track 12-2Stem or Progenitor cells
  • Track 12-3Neoplastic Transformations
  • Track 12-4Post-translational Modifications
  • Track 12-5Histone Variants

The Identification of epigenetic occasions discharged by particular natural and presence stressors, and these discoveries proceed to amplify our understanding of the mechanism of carcinogenesis, particularly those linked to risk-factor exposures and aging. In addition, important insights into epigenetic mechanisms and associated exposure risk factors have had a functional impact of specific human cancers. Environmental contaminants are linked to impacts on human health and consequences of combustion to contaminating trace metals and residual organic compounds used in daily life.


  • Track 13-1Carcinogen Evaluation
  • Track 13-2Ecological Epigenetics
  • Track 13-3Ecological Epigenetics
  • Track 13-4Infections and Microbiome
  • Track 13-5Early Life exposures

Genome editing is of great interest in the prevention and treatment of human diseases. Currently, most research on genome editing is done to understand diseases using cells and animal models. Ethical concerns arise when genome editing, using technologies such as CRISPR-Cas9, is used to alter human genomes. Most of the changes introduced with genome editing are limited to somatic cells, which are cells other than egg and sperm cells. These changes affect only certain tissues and are not passed from one generation to the next. However, changes made to genes in egg or sperm cells (germline cells) or in the genes of an embryo could be passed to future generations.


  • Track 14-1Genome Engineering
  • Track 14-2RNA editing
  • Track 14-3Disease Models
  • Track 14-4CRISPR in Cancer
  • Track 14-5Epigenomics

Epigenetic changes are believed to be a result of changes in an organism's environment that result in fixed and permanent changes in most differentiated cells. Some environmental changes that have been linked to epigenetic changes include starvation, folic acid, and various chemical exposures. There are periods in an organism's life cycle in which the organism is particularly susceptible to epigenetic influences; these include fertilization, gametogenesis, and early embryo development. Epigenetic influences might be involved in the regulation of foetal development and the pathophysiology of adult diseases such as cancer, diabetes, obesity, and neurodevelopmental disorders. Various epigenetic mechanisms may also be involved in the pathogenesis of preeclampsia and intrauterine growth restriction. Additionally, environmental exposures are being held responsible for causing epigenetic changes that lead to a disease process.


  • Track 15-1Histone code
  • Track 15-2MicroRNAs
  • Track 15-3Epigenetic Marks
  • Track 15-4DNA Methylations

The practices of personalized medicine are to maximize the therapeutic effects of likelihood and to minimize the risk of drug toxicity for an individual patient. Pharmacogenomics is the study of the genome in drug response. The genetic disorder occurrence is quite rare in population; some might be hereditary while the others are caused by mutations. Disease-specific epigenetic signatures such as DNA methylation, hydroxymethylation, and non-coding RNAs are now being utilized clinically for prognostics and diagnostics, while an expanding collection of genetically aberrant, abnormally expressed or chromatin-interacting epigenetic enzymes are positioned as promising targets for therapeutic intervention. Scientists also recognize that even as the knowledge base continues to expand, the clinical translation of that knowledge still requires empirical evidence, generated for a particular disease and drug combination, before treatment can be customized to a patient's genotype.


  • Track 16-1Genomic DNA and mRNA
  • Track 16-2Serotonin transporter gene

Epigenetic therapy is a relatively new treatment that is related to gene therapy, as the treatment looks at changes in the DNA. However, unlike gene therapy, which works to alter the DNA sequence, epigenetic therapy focuses on changes in DNA expression. Epigenetic drugs for cancer treatment have opened the door for the development of epigenetic drugs for other disorders including neurodegenerative diseases. The understanding of the contribution of epigenetic changes to rare diseases provides useful principles for other common and complex disorders such as cancer, cardiovascular, type 2 diabetes, obesity, and neurological diseases and will hopefully provide us with better molecular tools for an improved diagnosis, prognosis, and therapy for the patients in the future.



  • Track 17-1p53 Gene Therapy
  • Track 17-2Immunotherapy
  • Track 17-3Histone Deacetylase Inhibitors
  • Track 17-4DNA Methyltransferase Inhibitors
  • Track 17-5miRNA Biomarkers and Interventions
  • Track 17-6Epigenetics Yoga Therapy

It is the knowledge of epigenetics, combined with rising of technologies such as CRISPR/Cas9 gene editing and next-generation sequencing. In recent years, it permits us to superior recognize the interaction between epigenetic alter, quality direction, and human diseases, and will lead to the improvement of unused approaches for atomic determination and focused on molecular medicines over the clinical range. Recent technical advances such as ChIP-on-ChIP and ChIP-seq have started to convert epigenetic research. The advance knowledge in the field is to understand the basic biology and human diseases, the catalyzing adoption of epigenetics or epitranscriptomics methods. Finally, the advancement of current approaches, coupled with new technologies, will allow for the development of new therapies and therapeutic targets for human diseases associated with deficient RNA modifications.



  • Track 18-1Combating Diseases with Epigenetics Therapy
  • Track 18-2Epigenetics and Ethics
  • Track 18-3New Epigenetic Phenomena
  • Track 18-4Case reports on Molecular Biomarkers